GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track

GRI Bio, Inc.

2024-Q2 EPS reported -$8.82

Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).
Cash and equivalents $6.4M as of June 30, 2024; public offering in June raised $4.0M gross.
Cash expected to fund operations into Q1 2025; plans to raise additional funds.
GRI-0621 Phase 2a IPF biomarker study: interim data Q4 2024, topline data Q1 2025.
GRI-0803 SLE program progressing preclinically; IND-enabling contingent on funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.